| Fetal Hematopoiesis (DNB 2019/2)4 | 495 | 2019 |
| Describe the evolutionary development of the hemoglobin's from embryo to adult (DNB 2020/2)5 | 495 | 2020 |
| Describe the relationship among the various hemoglobin's in first year of life and their implication in diagnosing hereditary hemoglobinopathies (DNB 2020/2)5 | 495 | 2020 |
| Discuss the etiology and investigations in a case of Anemia (DNB 1994/1)25 | 496 | 1994 |
| Describe laboratory investigations in an infant with anemia and Briefly outline the interpretation of test results (DNB 1995/1)25 | 496 | 1995 |
| Severe anemia in the first year of life (DNB 2002/1)15 | 496 | 2002 |
| What is peripheral smear finding in (DNB 2005/1)2+2+2+2+2 a. Thalassemia Major b. Lead poisoning c. Megaloblastic anemia d. CRF e. Malaria | 496 | 2005 |
| List the causes of microcytic hypochromic anemia. How will you differentiate between iron deficiency anemia and thalassemia? Discuss Briefly the oral iron chelators (DNB 2008/1)10 | 496 | 2008 |
| Approach to anemia in a 2 year old child (DNB 2023/1)5 | 496 | 2023 |
| Lab testing for diagnosis and classification of anemia (DNB 2023/2)5 | 496 | 2023 |
| Peripheral Blood Smear in anemia (DCH 2023/2)5 | 496 | 2023 |
| Characteristic hematological features, laboratory findings and treatment of congenital hypoplastic anemia (Diamond Blackfan Anemia) (DNB 2015/2)3+3+4 | 497 | 2015 |
| Diamond Blackfan anemia-clinical features and treatment (DNB 2018/2)5 | 497 | 2018 |
| Megaloblastic anemia (DNB 2003/2)15 | 503 | 2003 |
| List the common causes of macrocytic anemia. Describe the laboratory diagnosis of megaloblastic anemia and treatment of juvenile pernicious anemia (DNB 2004/2)4+3+3 | 503 | 2004 |
| Clinico-hematological prole of Megaloblastic Anemia (DNB 2006/1)10 | 503 | 2006 |
| Discuss causes, clinical manifestations, laboratory findings and treatment of Folate deficiency anemia in children (DNB 2007/2)10 | 503 | 2007 |
| Enlist the common causes of macrocytic anemia. Describe the laboratory diagnosis and treatment of megaloblastic anemia (DNB 2009/2)2+3+5 | 503 | 2009 |
| Write short note on: Peripheral smear findings in iron deficiency and B12 deficiency anemia (DNB 2010/2)2.5+2.5 | 503 | 2010 |
| Diagnostic and management of Megaloblastic anemia (DNB 2019/1)5 | 503 | 2019 |
| Prevention of Iron Deficiency Anemia in children (DNB 1995/2)15 | 504 | 1995 |
| Management of Iron Deficiency anemia (DNB 1998/2)10 | 504 | 1998 |
| Enlist the causes and outline the Differential Diagnosis and treatment of iron deficiency anemia (DNB 2005/1)3+3+4 | 504 | 2005 |
| Outline the etiology of iron deficiency in children. Describe the clinical features and approach to diagnosis of a child suspected to be having nutritional anemia (DNB 2013/1)3+2+5 | 504 | 2013 |
| Describe the sequential pathological changes seen with iron deficiency states. What laboratory studies can be used to differentiate common microcytic anemias? (DNB 2013/2)5+5 | 504 | 2013 |
| Prevention of iron deficiency anaemia in children under 5 years of age (DNB 2018/1/5) | 504 | 2018 |
| Describe the iron metabolism in the human body (DNB 2022/1)5 | 504 | 2022 |
| Differential diagnosis and laboratory evaluation of iron-refractory iron deficiency anemia (DNB 2022/2)5 | 504 | 2022 |
| Treatment of iron deficiency anaemia in children (DNB 2023/1)5 | 504 | 2023 |
| Role of red cell indices in diagnosis of iron deficiency anemia (DNB 2024/1)5 | 504 | 2024 |
| Differential diagnosis of microcytic hypochromic anaemia (DNB 2018/2)5 | 505 | 2018 |
| Management of hypochromic microcytic anemia in children (DNB 2022/1)5 | 505 | 2022 |
| Diagnosis and management of Congenital Hereditary Spherocytosis (DNB 1997/1)15 | 507 | 1997 |
| Hereditary Spherocytosis (DNB 2006/1)10 | 507 | 2006 |
| Clinical features, diagnosis and management of hereditary spherocytosis (DNB 2024/2)5 | 507 | 2024 |
| Management of acute sickle cell crisis (DNB 1999/1)15 | 511 | 1999 |
| Acute clinical complications of Sickle cell disease (DNB 2017/2)6 | 511 | 2017 |
| Sickle cell crisis - Clinical presentation and management (DNB 2021/2)5 | 511 | 2021 |
| Pathophysiology of sickle cell disease (DNB 2023/2)5 | 511 | 2023 |
| Management of acute chest syndrome (DNB 2023/2)5 | 511 | 2023 |
| Clinical manifestations and treatment of sickle cell anemia (DNB 2024/1)4+2 | 511 | 2024 |
| Sickle cell crisis (DNB 2024/2)5 | 511 | 2024 |
| Methemoglobinemia- diagnosis and management (DNB 2017/2)4 | 511 | 2017 |
| Recent concepts/advances for treatment/management of Thalassemia major in children (DNB 1995/2)10 | 511 | 1995 |
| Current management of Thalassemia Major (DNB 1996/2)15 | 511 | 1996 |
| Newer modalities in the management of ẞ Thalassemia Major (DNB 1999/2)10 | 511 | 1999 |
| Antenatal diagnosis of Thalassemia (DNB 1999/2)15 | 511 | 1999 |
| Genetic basis of Thalassemia syndromes (DNB 2002/1)15 | 511 | 2002 |
| In relation to Thalassemia write a note on the following (DNB 2005/1)10 a. Alkali desaturation test b. NESTROFT test c. Peripheral smear d. SQUID-BLS e.BMD | 511 | 2005 |
| Alpha Thalassemia (DNB 2007/1)10 | 511 | 2007 |
| Outline the antenatal management of a mother with an earlier child with thalasemia major (DNB 2007/2)10 | 511 | 2007 |
| List the causes of microcytic hypochromic anemia. Provide differentiating features between iron deficiency anaemia and beta thalassemia trait. Describe the management of thalassemia major (DNB 2011/1)3+3+4 | 511 | 2011 |
| Outline the long term complications of thalassemia major. How will you monitor for such complications in a child with thalassemia major? (DNB 2013/1)5+5 | 511 | 2013 |
| Describe the foetal hemoglobins. Discuss the transfusion therapy for Thalassemia major and its long term follow up plan (DNB 2014/1)3+4+3 | 511 | 2014 |
| Recent concepts/advances for treatment/management of Thalassemia major in children (DNB 2014/2)5 | 511 | 2014 |
| Advances in treatment of Thalassemia major (DNB 2016/2)5 | 511 | 2016 |
| Iron chelation therapy (DNB 2017/1)5 | 511 | 2017 |
| Usual patterns in haemoglobin electrophoresis in beta thalassemia syndromes (DNB 2018/1)5 | 511 | 2018 |
| Indication of splenectomy in thalassemia (DNB 2018/2)5 | 511 | 2018 |
| Iron chelation therapy (DNB 2019/1)5 | 511 | 2019 |
| Counselling of an antenatal mother who has a thalassemia major child (DNB 2019/2)4 | 511 | 2019 |
| Management of transfusion in dependent thalassemia (DNB 2020/2)5 | 511 | 2020 |
| Genetic counselling and antenatal diagnosis of thalassemia (DNB 2022/2)5 | 511 | 2022 |
| Monitoring and management of iron overload in transfusion dependent thalassemia (DNB 2022/2)5 | 511 | 2022 |
| Long term complications of multi-transfused thalassemia major (DCH 2024/1)5 | 511 | 2024 |
| Pathogenesis of anemia in G6PD deficiency (DNB 1999/1)15 | 512 | 1999 |
| G6PD deficiency (DNB 1999/2)10 | 512 | 1999 |
| 3-year-old Child history of Jaundice since 2 months, H/O Exchange transfusion at D2. Discuss the differential diagnosis. Classify Hemolytic Anemia. Add a note on management of Intravascular hemolysis in G6PD deficiency (DNB 2005/1)4+4+2 | 512 | 2005 |
| Briefly outline normal erythropoiesis. Describe the diagnosis and treatment of G6PD deficiency (DNB 2007/2)10 | 512 | 2007 |
| Enlist the red blood cell metabolic enzyme pathways and the enzymes responsible for hemolysis. Discuss the pathogenesis involved in these hemolytic anemias (DNB 2011/1)3+7 | 512 | 2011 |
| Discuss the etiology and management of Autoimmune Hemolytic Anemia (DNB 2009/1)3+7 | 513 | 2009 |
| Discuss the etiology, pathogenesis and diagnostic workup of acute autoimmune hemolytic anemia (DNB 2010/2)3+3+4 | 513 | 2010 |
| Diagnosis and management of Autoimmune Hemolytic Anemia (DNB 2015/1)3 | 513 | 2015 |
| Management of Aplastic anemia (DNB 2016/1)5 | 517 | 2016 |
| Management of Aplastic anemia (DNB 2019/1)5 | 517 | 2019 |
| Fanconi anemia (DCH 2024/1)5 | 517 | 2024 |
| Classify causes of acquired pancytopenia. Write Briefly about the management of acquired aplastic anemia (DNB 2009/1)3+7 | 518 | 2009 |
| Define pancytopenia. Enlist the causes and assessment of severity of aplastic anemia in children (DNB 2010/1)2+4+4 | 518 | 2010 |
| Define pancytopenia. Enumerate common causes in children. How will you assess severity of acquired anemia in children? (DNB 2011/2)2+3+5 | 518 | 2011 |
| Evaluation of child with pancytopenia (DNB 2020/1)5 | 518 | 2020 |
| Transfusion of Blood fractions (DNB 2000/1)10 | 519 | 2000 |
| Precautions to be taken while transfusing haemolytic child (DNB 2019/2)4 | 519 | 2019 |
| Indications of Blood Component Therapy (DNB 2020/1)5 | 519 | 2020 |
| Enumerate the indication of platelet transfusion in paediatrics (DNB 2019/1)5 | 520 | 2019 |
| Platelet transfusion therapy (DNB 2024/1)4 | 520 | 2024 |
| Outline the method of extracting various blood components. What are the indications of usage of Fresh Frozen Plasma (FFP) and cryoprecipitate? (DNB 2009/2)5+5 | 522 | 2009 |
| Discuss the inherent hazards of Blood Transfusion in children and the necessary measures to avoid and minimize them (DNB 2007/1)10 | 523 | 2007 |
| Discuss Briefly the risks associated with blood transfusion therapy (DNB 2013/2)10 | 523 | 2013 |
| Transfusion associated hepatitis. Diagnosis and management (DNB 2017/1)5 | 523 | 2017 |
| Complications of blood transfusion (DNB 2022/1)5 | 523 | 2022 |
| Differentiate bleeding disorder from clotting disorder (DNB 2016/2)3 | 524 | 2016 |
| Draw a diagrammatic representation of coagulation cascade (DNB 2017/1)5 | 524 | 2017 |
| What are the components of haemostatic process? Outline the coagulation cascade (DNB 2019/1)5 | 524 | 2019 |
| Role and function of platelets in physiology of haemostasis (DNB 2020/1)5 | 524 | 2020 |
| Role of platelet in hemostasis (DNB 2022/2)5 | 524 | 2022 |
| Coagulation Cascade (DNB 2023/2)5 | 524 | 2023 |
| Describe coagulation pathway (DNB 2024/1)5 | 524 | 2024 |
| Antenatal diagnosis and carrier detection of Hemophilia (DNB 1998/2)15 | 525 | 1998 |
| Explain coagulation cascade. A 4-year-old child with h/o recurrent epistaxis and gum bleeding. Discuss laboratory diagnosis and management of this condition. Add a note of differentiating a bleeding disorder from a coagulation disorder (DNB 2005/1)5+3+2 | 525 | 2005 |
| A 5-year-old male child comes with a history of trivial fall and swelling of right knee. He has history of easy bruisability. Discuss the laboratory diagnosis and management of this child. Add a note on antenatal diagnosis and counselling (DNB 2006/1)10 | 525 | 2006 |
| Discuss the various aspects of management of a child with Hemophilia A (DNB 2007/2)10 | 525 | 2007 |
| A 10-year-old boy with hemophilia A, weighing 30 kg has come with bleeding in both knee joints. Discuss Briefly the specific, supportive and prophylactic management of this child (DNB 2011/1)4+3+3 | 525 | 2011 |
| Investigation and treatment of a 2-year-old boy presenting with spontaneous hemarthrosis (DNB 2016/2)10 | 525 | 2016 |
| Factor replacement therapy in haemophilia (DNB 2017/1)5 | 525 | 2017 |
| Specific treatment of mild to moderate bleeding in Haemophilia A (DNB 2018/1)5 | 525 | 2018 |
| Advance in treatment of hemophilia (DNB 2019/1)5 | 525 | 2019 |
| Prophylaxis program in haemophilia (DNB 2019/2)4 | 525 | 2019 |
| Recent advances in management of Haemophilia (DNB 2021/2)5 | 525 | 2021 |
| Oral drugs in management of hemophilia (DNB 2022/1)5 | 525 | 2022 |
| Discuss the differential diagnosis in a 6-year-old child with easy bruisability. Enumerate relevant investigation for each differential diagnosis (DNB 2023/1)5+5 | 525 | 2023 |
| Management of Hemophilia A (DNB 2023/2)5 | 525 | 2023 |
| Recent advances in management of Hemophilia A (DNB 2024/2)5 | 525 | 2024 |
| Von Willebrand disease (DNB 2020/1)5 | 526 | 2020 |
| Hereditary prothrombotic state (DNB 2021/1)5 | 527 | 2021 |
| Pathophysiology of thrombophilia (DNB 2016/1)4 | 528 | 2016 |
| Thrombotic disorders in children (DNB 2023/2)5 | 528 | 2023 |
| DIC (DNB 1996/2)15 | 532 | 1996 |
| Discuss the pathogenesis of disseminated intravascular coagulation (DIC) and relate it to the laboratory abnormalities observed in this entity (DNB 2008/1)10 | 532 | 2008 |
| Diagrammatically outline the Normal Coagulation Cascade. Outline diagnosis and management of disseminated Intravascular Coagulation (DIC) (DNB 2009/1)4+6 | 532 | 2009 |
| Disseminated intravascular coagulation: a) Etiology b) Diagnosis c) Treatment (DCH 2024/2)3+3+4 | 532 | 2024 |
| Management of Neonatal Thrombocytopenic Purpura (DNB 2000/1)15 | 533 | 2000 |
| Write differential diagnosis of a 5-year-old child with petechial rash with fever. How will you manage a child with idiopathic thrombocytopenic purpura (DNB 2004/2)4+6 | 533 | 2004 |
| Various treatment modalities in acute ITP (DNB 2006/1)10 | 533 | 2006 |
| Discuss etiopathogenesis, diagnosis and management of a Bleeding Neonate (DNB 2006/2)10 | 533 | 2006 |
| Write in brief regarding the etiology and management of idiopathic thrombocytopenic purpura (ITP) (DNB 2011/1)4+6 | 533 | 2011 |
| Discuss the treatment options for acute ITP in a 14-year-old girl child (DNB 2013/1)10 | 533 | 2013 |
| An 8-year-old girl has presented with epistaxis, bleeding gum and ecchymotic patches over trunk. Her platelet count is 20,000/cubic mm. Discuss the differential diagnosis with specific clinical investigative pointers. Plan the diagnostic work up for this child (DNB 2013/2)3+3+2+2 | 533 | 2013 |
| Management of ITP (DNB 2017/1)5 | 533 | 2017 |
| Management of chronic ITP (DNB 2018/2)5 | 533 | 2018 |
| Management of 1st episode of ITP (DNB 2019/2)5 | 533 | 2019 |
| Discuss the approach to neonate with thrombocytopenia with specific reference to causes and investigations (DNB 2019/2)6 | 533 | 2019 |
| Immune Thrombocytopenic Purpura - Management Guidelines (DNB 2021/2)5 | 533 | 2021 |
| Neonatal thrombocytopenia (DNB 2023/2)5 | 533 | 2023 |
| Management of ITP in children (DCH 2024/1)5 | 533 | 2024 |
| Outline the management of recurrent ITP in a six year old child (DNB 2024/2)5 | 533 | 2024 |
| Neonatal alloimmune thrombocytopenia (NAIT) (DNB 2024/2)5 | 533 | 2024 |
| Outline the functions of Spleen. Describe the indications and complication of splenectomy and post-operative management (DNB 2009/1)3+7 | 534 | 2009 |
| Describe the functions of spleen. Describe clinical manifestations and management of asplenia/polysplenia (DNB 2010/1)4+3+3 | 534 | 2010 |
| Clinical approach to microcytic anemia in a child (DNB 2025/1)5 | 504 | 2025 |
| Clinical features, diagnosis and management of hereditary spherocytosis (DNB 2024/2)5 | 507 | 2024 |
| Chelation therapy in thalassemia major on transfusion therapy (DNB 2025/1)5 | 511 | 2025 |
| Sickle cell crisis (DNB 2024/2)5 | 511 | 2024 |
| Therapeutic uses of erythropoietin (DNB 2024/2)5 | 519 | 2024 |
| Recent advances in management of Hemophilia A (DNB 2024/2)5 | 525 | 2024 |
| Outline management of recurrent immune thrombocytopenic purpura (ITP) in a child (DNB 2024/2)5 | 533 | 2024 |
| Neonatal alloimmune thrombocytopenia (NAIT) (DNB 2024/2)5 | 533 | 2024 |
| Laboratory findings & management of Autoimmune Hemolytic Anemia (AIHA) in a child (DNB 2025/1)5 | 513 | 2025 |